Metropolitan Life Insurance Company (MetLife)’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,885	Closed	-$202K	–	2543
2023 Q1	$202K	Sell	1,885 -275	-13%	-$31.7K	0.01%	661
2022 Q4	$238K	Buy	2,160 +368	+21%	+$23.9K	0.01%	646
2022 Q3	$106K	Hold	1,792	–	–	0.01%	983
2022 Q2	$50.6K	Hold	1,792	–	–	﹤0.01%	1502
2022 Q1	$67.7K	Sell	1,792 -6,532	-78%	-$258K	﹤0.01%	1424
2021 Q4	$329K	Buy	8,324 +4,609	+124%	+$144K	﹤0.01%	1693
2021 Q3	$88.1K	Buy	+3,715	New	+$87.7K	﹤0.01%	2598

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s RXDX Position: Q2 2023 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 1,885 shares — an estimated $202K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in RXDX in Q3 2021 and held it in 7 quarters. The position peaked at $329K in Q4 2021. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Metropolitan Life Insurance Company (MetLife) reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 1,885 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $202K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Prometheus Biosciences, Inc. Common Stock in Q3 2021 and held it in 7 quarters.
Metropolitan Life Insurance Company (MetLife)'s Prometheus Biosciences, Inc. Common Stock position peaked at $329K in Q4 2021.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2023, filed 10 Aug 2023.